FibroBiologics Inc. (FBLG) just hit a key milestone in its quest to treat diabetic foot ulcers (DFUs). On Monday, the company announced it has released the first batch of its investigational therapy CYWC628 for use in a Phase 1/2 clinical trial. The drug product was manufactured under the FDA's current Good Manufacturing Practices (cGMP) and passed all required safety and quality checks, so it's now ready for clinical testing.
This follows the company's recent completion of the first cGMP batch of CYWC628. For those keeping score at home, FibroBiologics is a clinical-stage biotech focused on fibroblast cell-based therapies for chronic diseases. CYWC628 is a fibroblast-based therapy designed specifically to help heal diabetic foot ulcers, a serious complication of diabetes that can lead to amputations if not treated effectively.
The Phase 1/2 trial will evaluate the safety, tolerability, and preliminary efficacy of CYWC628 in patients with DFUs. The company expects to share interim results in the third quarter of 2026, with complete primary safety and efficacy data coming by the end of the year. That's a pretty clear timeline for investors to watch.
"With the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1/2 DFU trial," said Pete O'Heeron, Founder and CEO of FibroBiologics. Enrollment is the next big step, and getting there means the company has cleared a significant regulatory and manufacturing hurdle.
On the financing side, FibroBiologics raised $3 million in April through a public offering of 2.27 million shares and warrants to purchase up to 2.272 million shares, all at a combined price of $1.32. The warrants have an exercise price of $1.32 per share. That gives the company some runway to advance the trial.
But the news isn't just about the DFU trial. In December 2025, FibroBiologics filed a new patent application with the U.S. Patent and Trademark Office covering a proprietary fibroblast-derived therapy platform for orthopedic and musculoskeletal conditions. Think degenerative disc repair, cartilage repair, and joint restoration. The patent, if granted, would protect the company's technology that uses fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids to support structural and functional repair in orthopedic tissues. It's a broader play that could expand the company's reach beyond DFUs.
As for the stock, FBLG shares were down 4.79% at $1.39 in premarket trading on Monday. Over the past month, the stock has gained about 2.2%, while the S&P 500 rose 9.9%. Year-to-date, FBLG is down roughly 71%, compared to the S&P 500's 5.1% gain. So it's been a rough ride, but the trial progress could be a catalyst if the data looks good.
